دورية أكاديمية
أعرض في EDS

BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.

التفاصيل البيبلوغرافية
العنوان: BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
المؤلفون: Graf JF; Computational Biology and Biostatistics Laboratory, General Electric Global Research Center, One Research Circle, Niskayuna, NY 12309, USA., Scholz BJ, Zavodszky MI
المصدر: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2012 Feb; Vol. 39 (1), pp. 37-54. Date of Electronic Publication: 2011 Dec 10.
نوع المنشور: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-8744 (Electronic) Linking ISSN: 1567567X NLM ISO Abbreviation: J Pharmacokinet Pharmacodyn Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Springer
Original Publication: Bristol, England ; New York, N.Y. : Kluwer Academic/Plenum Publishers, c2001-
مواضيع طبية MeSH: Computer Simulation* , Models, Biological* , Pharmacokinetics*, Algorithms ; Animal Structures/metabolism ; Animals ; Biological Transport/physiology ; Biotransformation/physiology ; Body Fluids/metabolism ; Cefotaxime/analogs & derivatives ; Cefotaxime/pharmacokinetics ; Cephalosporins/pharmacokinetics ; Contrast Media/pharmacokinetics ; Databases, Factual ; Eukaryotic Cells/metabolism ; Guinea Pigs ; Haplorhini ; Humans ; Internet ; Iohexol/pharmacokinetics ; Mice ; Pharmaceutical Preparations/blood ; Pharmaceutical Preparations/chemistry ; Pharmaceutical Preparations/metabolism ; Rats ; Reproducibility of Results ; Software ; Tissue Distribution/physiology ; User-Computer Interface ; Cefpirome
مستخلص: We developed a detailed, whole-body physiologically based pharmacokinetic (PBPK) modeling tool for calculating the distribution of pharmaceutical agents in the various tissues and organs of a human or animal as a function of time. Ordinary differential equations (ODEs) represent the circulation of body fluids through organs and tissues at the macroscopic level, and the biological transport mechanisms and biotransformations within cells and their organelles at the molecular scale. Each major organ in the body is modeled as composed of one or more tissues. Tissues are made up of cells and fluid spaces. The model accounts for the circulation of arterial and venous blood as well as lymph. Since its development was fueled by the need to accurately predict the pharmacokinetic properties of imaging agents, BioDMET is more complex than most PBPK models. The anatomical details of the model are important for the imaging simulation endpoints. Model complexity has also been crucial for quickly adapting the tool to different problems without the need to generate a new model for every problem. When simpler models are preferred, the non-critical compartments can be dynamically collapsed to reduce unnecessary complexity. BioDMET has been used for imaging feasibility calculations in oncology, neurology, cardiology, and diabetes. For this purpose, the time concentration data generated by the model is inputted into a physics-based image simulator to establish imageability criteria. These are then used to define agent and physiology property ranges required for successful imaging. BioDMET has lately been adapted to aid the development of antimicrobial therapeutics. Given a range of built-in features and its inherent flexibility to customization, the model can be used to study a variety of pharmacokinetic and pharmacodynamic problems such as the effects of inter-individual differences and disease-states on drug pharmacokinetics and pharmacodynamics, dosing optimization, and inter-species scaling. While developing a tool to aid imaging agent and drug development, we aimed at accelerating the acceptance and broad use of PBPK modeling by providing a free mechanistic PBPK software that is user friendly, easy to adapt to a wide range of problems even by non-programmers, provided with ready-to-use parameterized models and benchmarking data collected from the peer-reviewed literature.
References: Curr Top Med Chem. 2003;3(10):1125-54. (PMID: 12769713)
AAPS J. 2009 Mar;11(1):155-66. (PMID: 19280352)
Biochem Pharmacol. 1994 Apr 29;47(9):1469-79. (PMID: 8185657)
Adv Drug Deliv Rev. 1998 Oct 5;34(1):93-108. (PMID: 10837672)
Drug Discov Today Technol. 2004 Dec;1(4):449-56. (PMID: 24981626)
Pharm Res. 2009 Dec;26(12):2543-50. (PMID: 19847627)
Am J Physiol Renal Physiol. 2007 Jan;292(1):F430-9. (PMID: 16954345)
Drug Metab Dispos. 2006 Jan;34(1):94-101. (PMID: 16221756)
BMC Res Notes. 2009 Aug 05;2:158. (PMID: 19656378)
AAPS PharmSci. 2004 Feb 09;6(1):E6. (PMID: 15198507)
J Am Soc Nephrol. 1995 Aug;6(2):257-63. (PMID: 7579093)
Genes Dev. 2003 Mar 1;17(5):545-80. (PMID: 12629038)
Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):235-49. (PMID: 17428153)
Xenobiotica. 2007 Oct-Nov;37(10-11):1295-310. (PMID: 17968746)
Bioorg Med Chem. 2007 Jun 1;15(11):3756-67. (PMID: 17418579)
J Magn Reson Imaging. 2008 Jun;27(6):1388-98. (PMID: 18504759)
Kidney Int. 2006 Feb;69(3):440-9. (PMID: 16514429)
Adv Drug Deliv Rev. 2002 Mar 31;54(3):433-51. (PMID: 11922957)
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1143-52. (PMID: 18721109)
Drug Metab Dispos. 2006 Jan;34(1):84-93. (PMID: 16221757)
Curr Opin Drug Discov Devel. 2009 Jul;12(4):509-18. (PMID: 19562647)
Metabolism. 1998 Apr;47(4):484-92. (PMID: 9550550)
Q J Exp Physiol. 1985 Jul;70(3):347-56. (PMID: 3898188)
Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):193-9. (PMID: 15733214)
Am J Physiol. 1994 Sep;267(3 Pt 1):L223-41. (PMID: 7943249)
Eur J Pharm Biopharm. 2008 May;69(1):1-9. (PMID: 17826969)
Curr Top Med Chem. 2003;3(11):1257-68. (PMID: 12769704)
IEEE Trans Biomed Eng. 2007 Mar;54(3):538-42. (PMID: 17355068)
Nat Rev Drug Discov. 2003 Mar;2(3):192-204. (PMID: 12612645)
Contrast Media Mol Imaging. 2007 Sep-Oct;2(5):215-28. (PMID: 17874424)
IEEE Trans Med Imaging. 2010 Mar;29(3):699-707. (PMID: 19758856)
J Pharmacol Exp Ther. 1995 Nov;275(2):933-40. (PMID: 7473185)
J Histochem Cytochem. 2005 Sep;53(9):1087-97. (PMID: 15923354)
Pharmacol Ther. 1990;47(2):281-328. (PMID: 2203072)
J Cell Biol. 1974 Jan;60(1):128-52. (PMID: 4129076)
Int J Biomed Imaging. 2011;2011:953806. (PMID: 21860614)
J Pharm Sci. 2005 Oct;94(10):2327-43. (PMID: 16136543)
Physiol Rev. 1994 Jan;74(1):163-219. (PMID: 8295933)
BMC Clin Pharmacol. 2002 Aug 15;2:5. (PMID: 12182760)
J Pharmacokinet Biopharm. 1995 Apr;23(2):217-29. (PMID: 8719238)
Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):619-28. (PMID: 16859409)
Antimicrob Agents Chemother. 1996 Dec;40(12):2703-9. (PMID: 9124826)
المشرفين على المادة: 0 (Cephalosporins)
0 (Contrast Media)
0 (Pharmaceutical Preparations)
4419T9MX03 (Iohexol)
N2GI8B1GK7 (Cefotaxime)
Z31298J4HQ (cefodizime)
تواريخ الأحداث: Date Created: 20111214 Date Completed: 20120927 Latest Revision: 20231213
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3258408
DOI: 10.1007/s10928-011-9229-x
PMID: 22161221
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-8744
DOI:10.1007/s10928-011-9229-x